Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma

Clinical Cancer Research

Volumn 6, Issue 11, 2000, Pages 4205-4208

  Vaishampayan, Uika ^a   Glode, Michael ^c   Du, Wei ^b   Kraft, Andrew ^c   Hudes, Gary ^d   Wright, Jeremy ^e   Hussain, Maha ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOLASTATIN 10; ESTRAMUSTINE; ETOPOSIDE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; MALE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OLIGOPEPTIDES; PROSTATIC NEOPLASMS;

EID: 0033739893     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Cancer statistics 2000
2. Chemotherapy with mitoxantrone plus prednisone or prednisone alone of symptomatic hormone resistant prostate cancer. A Canadian randomized trial with palliative endpoints
3. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
4. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone
5. A Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate
6. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone refractory prostate cancer
7. Phase I trial of docetaxel (D) with estramustine (E) in androgen independent prostate cancer
8. Phase II trial of oral estramustine, oral etoposide and intravenous paclitaxel in hormone refractory prostate cancer
9. The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10
10. Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans
11. Antineoplastic agents 365. Dolastatin 10 SAR probes
12. The dolastatins, a family of promising antineoplastic agents
13. Dolastatin induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines
14. Activity of dolastatin-10 against small cell lung cancer in vitro and in vivo: Induction of apoptosis and bcl-2 modification
15. Treatment of human prostate cancer cells with dolastatin-10, a peptide isolated from a marine shell-less mollusc
16. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer
17. Overexpression of bcl-2 protects cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
18. Reporting results of cancer treatment
19. Continuous infusion vinblastine for advanced hormone refractory prostate cancer
20. Taxol in advanced hormone refractory carcinoma of the prostate: A Phase II trial of the Eastern Cooperative Oncology Group
21. Oral etoposide in the treatment of hormone refractory prostate cancer
22. Phase II study of estramustine and vinblastine, two microtubule inhibitors in hormone refractory prostate cancer
23. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network Phase III trial
24. Dolastatin-10 a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the Vinca alkaloid binding domain
25. Binding of dolastatin-10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and Vinca alkaloid sites
26. Interaction of dolastatin-10 with tubulin: Induction of aggregation and binding and dissociation reactions
27. Bcl-2 is the guardian of microtubule integrity
28. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma
29. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1
30. A new tubulin polymerization inhibitor auristatin PE, induces tumor recession in a human Wadenstrom's macroglobulinemia xenograft model
31. A Phase I, pharmacokinetic/pharmacodynamic study of dolostatin-10 in adult patients with advanced solid tumors
32. Phase I trial of dolastatin l0 (NSC376128) in patients with advanced solid tumors